Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CDC42 | P60953 | 1/20 | 0.43 |
| ▸ | RAC1 | P63000 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109480 | 0.80 | CA1 (0.58) | CYP2A6KDM4ERAB9AMEN1MAPK1 | |
| SCHEMBL443070 | 0.79 | CYP1A2 (0.79) | CYP1A2CYP2A6HSD17B1HSD17B2ABCB11 | |
| SCHEMBL29447161 | 0.79 | CYP1A2 (0.79) | CYP1A2CYP2A6HSD17B1HSD17B2ABCB11 | |
| Bromide SCHEMBL1271263 | 0.78 | CA1 (0.55) | CYP2A6KDM4ERAB9AMEN1MAPK1 | |
| SCHEMBL9220678 | 0.78 | CA1 (0.55) | KDM4ERAB9AMEN1MAPK1KMT2A | |
| SCHEMBL29411044 | 0.77 | ACHE (0.50) | RAB9ANPC1 | |
| SCHEMBL24031 | 0.77 | ACHE (0.50) | RAB9ANPC1 | |
| SCHEMBL4995694 | 0.76 | CA12 (0.46) | KDM4EMAPK1 | |
| SCHEMBL6891918 | 0.74 | CYP1A2 (0.71) | CYP1A2CYP2A6HSD17B1HSD17B2ABCB11 | |
| SCHEMBL443528 | 0.74 | CYP2A6 (0.80) | CYP1A2CYP2A6HSD17B1HSD17B2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| US-6369265-B1 | HETEROCOUPLING REACTION, MIXING IN A LIQUID AN ARYL HALIDE, BONDING TO AROMATIC RINGS, GRIGNARD REACTION, METAL COMPOUND AND HETEROCYCLIC CARBENE | UNIVERSITY OF NEW ORLEANS RESEARCH & TECHNOLOGY FOUNDATION | 2002-04-09 | — | — | US | claimed |
| WO-2001066248-A2 | C-C AND C-N COUPLING CATALYST COMPRISING TRANSITION METAL AND CARBENE | UNIVERSITY OF NEW ORLEANS RESEARCH AND TECHNOLOGY FOUNDATION (US) | 2001-09-13 | — | — | WO | claimed |
| US-20240262845-A1 | PYRIDINIUM SALTS, METHODS OF MAKING, AND METHODS OF USE | UNIV WYOMING (US) | 2024-08-08 | — | — | US | disclosed |
| US-20240262844-A1 | PYRIDINIUM SALTS AND METHODS OF USE | UNIV WYOMING (US) | 2024-08-08 | — | — | US | disclosed |
| WO-2024155932-A1 | PYRIDINIUM SALTS AND METHODS OF USE | UNIVERSITY OF WYOMING (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024155935-A2 | PYRIDINIUM SALTS, METHODS OF MAKING, AND METHODS OF USE | UNIVERSITY OF WYOMING (US) | 2024-07-25 | — | — | WO | disclosed |
| CN-117069717-A | 2, 6-naphthyridine micromolecule derivative and preparation method thereof | 江汉大学 | 2023-11-17 | — | — | CN | disclosed |
| US-7622604-B2 | via grignard intermediate such as benzylmagnesium chloride and esterification with succinic anhydride; inflammatory and cardiovascular diseases; optimizes the amount of monoester in the final product mixture and minimizes the amount of reagents; e.g. synthesis of succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2009-11-24 | — | — | US | disclosed |
| EP-0081993-B1 | OPTICALLY ACTIVE ALPHA-SUBSTITUTED ARYL KETONES, THEIR PREPARATION AND THEIR USE IN PREPARING ALPHA-ARYLALKANOIC ACIDS | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1988-08-17 | — | — | EP | disclosed |
| US-4749804-A | Preparation of stereoisomers of ketals | SYNTEX (U.S.A.) INC. (US) | 1988-06-07 | — | — | US | disclosed |
| US-4605758-A | Preparation of α-arylalkanoic acids | SYNTEX PHARMACEUTICALS INTERNATIONAL LTD. (BM) | 1986-08-12 | — | — | US | disclosed |
| US-4496755-A | Optically active 1-(6-methoxy-2-naphthyl)-2-(alkoxycarbonyl) amino-1-propanone, its derivatives and their halo analogs and the methods for their manufacture | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-01-29 | — | — | US | disclosed |
| EP-0091757-A1 | Optically active 1-(6-methoxy-2-naphthyl)-2-alkoxycarbonyl)amino-1-propanone, its derivatives and their halo anlogs, and methods for their manufacture | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1983-10-19 | — | — | EP | disclosed |
| EP-0081993-A2 | Optically active alpha-substituted aryl ketones, their preparation and their use in preparing alpha-arylalkanoic acids | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1983-06-22 | — | — | EP | disclosed |
| US-3975432-A | Process for preparing 2-(6-methoxy-2-naphthyl)propionic acid | SYNTEX CORPORATION (PM) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262845-A1 | PYRIDINIUM SALTS, METHODS OF MAKING, AND METHODS OF USE | KYNU, TPH1, AADAT | CYP1A2 1509/4885CYP2A6 506/4885HSD17B1 4534/4885 |
| US-20240262844-A1 | PYRIDINIUM SALTS AND METHODS OF USE | KYNU, TPH1, AADAT | CYP1A2 1399/4885CYP2A6 605/4885HSD17B1 4601/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | CYP1A2 394/4885CYP2A6 355/4885HSD17B1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.